The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 3, 2014, Pages 628-639

  An, Wen Qi ^a,b   Su, Zhi Guo ^b   Pan, Ruo Wen ^a   Yang, Bao Ping ^a   Zhang, Yong Chao ^a   Shi, Liang ^a   Li, Qing ^a  

^a Hualan Biological Engineering Inc   (China)

^b INSTITUTE OF PROCESS ENGINEERING   (China)

Author keywords

Challenge systems immunogenicity; Coxsackievirus A16; Enterovirus; Vaccine

Indexed keywords

COXSACKIEVIRUS A16 VACCINE; INACTIVATED VIRUS VACCINE; MATERNAL ANTIBODY; PROPIOLACTONE; UNCLASSIFIED DRUG; DISINFECTANT AGENT; INACTIVATED VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHINA; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; LD 50; MACACA FASCICULARIS; MOUSE; NEWBORN; NONHUMAN; PASSIVE IMMUNIZATION; RAT; VACCINATION; VACCINE PRODUCTION; VIRUS ISOLATION; VIRUS LOAD; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BLOOD; COXSACKIEVIRUS INFECTIONS; DRUG EFFECTS; ENTEROVIRUS; FEMALE; IMMUNOLOGY; LD50; METABOLISM; SPRAGUE DAWLEY RAT; SURVIVAL ANALYSIS; VIRUS INACTIVATION;

ANIMALS; ANTIBODIES, VIRAL; COXSACKIEVIRUS INFECTIONS; DISINFECTANTS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENTEROVIRUS; FEMALE; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION, PASSIVE; LETHAL DOSE 50; MACACA FASCICULARIS; MICE, INBRED BALB C; PROPIOLACTONE; RATS, SPRAGUE-DAWLEY; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VIRAL VACCINES; VIRUS INACTIVATION;

EID: 84898436560     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27295     Document Type: Article

References (31)

1. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB, et al.; For the Outbreak Study Group. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. Clin Infect Dis 2000; 31:678-83; PMID:11017815; http://dx.doi.org/10.1086/314032
2. Centers for Disease Control and Prevention (CDC). Deaths among children during an outbreak of hand, foot, and mouth disease - Taiwan, Republic of China, April-July 1998. MMWR Morb Mortal Wkly Rep 1998; 47:629-32; PMID:9704628
3. Pallansch M, Roos R. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p 839-93 In Knipe DM, et al., editors. (ed), Fields virology, 5th ed Lippincott Williams & Wilkins, Philadelphia, PA.
4. Zhu J, Luo Z, Wang J, Xu Z, Chen H, Fan D, Gao N, Ping G, Zhou Z, Zhang Y, et al. Phylogenetic analysis of Enterovirus 71 circulating in Beijing, China from 2007 to 2009. PLoS One 2013; 8:e56318; PMID:23418551; http://dx.doi.org/10. 1371/journal.pone.0056318
5. Huang XY, Kang K, Xu YL, Wei HY, Li XL, Ma H, You AG, Chen HM, Xu BL. [Etiology surveillance of hand-foot-mouth disease in Henan province between 2008 and 2011]. Zhonghua Yu Fang Yi Xue Za Zhi 2012; 46:883-7; PMID:23363860
6. Christensen A, Nordbø SA. [Enterovirus infections diagnosed in middle Norway during the period 1992-2001]. Tidsskr Nor Laegeforen 2003; 123:3180-3; PMID:14714003
7. Kusuda H, Kitamura S. Localization of coxsackie A16 viral antigen in various organs of newborn mice by the fluorescent antibody technique. Jpn J Microbiol 1974; 18:411-3; PMID:4613901; http://dx.doi.org/10.1111/j.1348-0421. 1974.tb00828.x
8. Sickles GM, Mutterer M, Feorino P, Plager H. Recently classified types of Coxsackie virus, group A; behavior in tissue culture. Proc Soc Exp Biol Med 1955; 90:529-31; PMID:13273503; http://dx.doi.org/10.3181/00379727-90-22088
9. Oberste MS, Peñaranda S, Maher K, Pallansch MA. Complete genome sequences of all members of the species Human enterovirus A. J Gen Virol 2004; 85:1597-607; PMID:15166444; http://dx.doi.org/10.1099/vir.0.79789-0
10. Pöyry T, Hyypiä T, Horsnell C, Kinnunen L, Hovi T, Stanway G. Molecular analysis of coxsackievirus A16 reveals a new genetic group of enteroviruses. Virology 1994; 202:982-7; PMID:8030260; http://dx.doi.org/10. 1006/viro.1994.1423
11. Wang CY, Li Lu F, Wu MH, Lee CY, Huang LM. Fatal coxsackievirus A16 infection. Pediatr Infect Dis J 2004; 23:275-6; PMID:15014311; http://dx.doi.org/10.1097/01.inf.0000115950.63906.78
12. Xu W, Liu CF, Yan L, Li JJ, Wang LJ, Qi Y, Cheng RB, Xiong XY. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 2012; 9:8; PMID:22230340; http://dx.doi.org/10.1186/1743-422X-9-8
13. Chen CW, Lee YP, Wang YF, Yu CK. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine 2011; 29:2772-6; PMID:21315698; http://dx.doi.org/10.1016/j.vaccine.2011.01.094
14. Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 2010; 84:661-5; PMID:19864378; http://dx.doi.org/10.1128/JVI. 00999-09
15. Polley JR, Guerin MM. The use of beta-propiolactone for the preparation of virus vaccines. I. Selection of reaction conditions. Can J Microbiol 1957; 3:863-70; PMID:13472511; http://dx.doi.org/10.1139/m57-095
16. Polley JR, Guerin MM. The use of beta-propiolactone for the preparation of virus vaccines. II. Antigenicity. Can J Microbiol 1957; 3:871-7; PMID:13472512; http://dx.doi.org/10.1139/m57-096
17. Iwai M, Masaki A, Hasegawa S, Obara M, Horimoto E, Nakamura K, Tanaka Y, Endo K, Tanaka K, Ueda J, et al. Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis 2009; 62:254-9; PMID:19628900
18. Ranganathan S, Singh S, Poh CL, Chow VT. The hand, foot and mouth disease virus capsid: sequence analysis and prediction of antigenic sites from homology modelling. Appl Bioinformatics 2002; 1:43-52; PMID:15130856
19. Reed LJ, Muench H. A simple method of estimating 50 percent end-points. Am J Hyg 1938; 27:493-7
20. Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, Cai F, Gao Z, McMinn PC. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011; 29:4829-38; PMID:21550375; http://dx.doi.org/10.1016/j.vaccine.2011.04.070
21. Kamaraj G, Lakshmi Narasu M, Srinivasan VA. Validation of betapropiolactone (BPL) as an inactivant for infectious bovine rhinotracheitis (IBR) virus. Res Vet Sci 2008; 85:589-94; PMID:18262212; http://dx.doi.org/10. 1016/j.rvsc.2007.12.009
22. Refaie FM, Esmat AY, Mohamed AF, Mohamed WA. The effect of chemical inactivation of bovine viral diarrhea virus with beta-propiolactone and binary ethyleneimine on plasma proteins and coagulation factors. Egypt J Immunol 2004; 11:9-20; PMID:16734113
23. Cai Y, Liu Q, Huang X, Li D, Ku Z, Zhang Y, Huang Z. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013; 31:2215-21; PMID:23499596; http://dx.doi.org/10.1016/j.vaccine.2013.03.007
24. Liu Q, Yan K, Feng Y, Huang X, Ku Z, Cai Y, Liu F, Shi J, Huang Z. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 2012; 30:6642-8; PMID:22959985; http://dx.doi.org/10.1016/j.vaccine.2012.08.071
25. Herrlich A, Epp C, Mayr A. [Animal experimental studies on various smallpox vaccines in a cowpox challenge experiment on white mice]. Z Immunitatsforsch Allerg Klin Immunol 1968; 135:237-45; PMID:4301159
26. Dong C, Wang J, Liu L, Zhao H, Shi H, Zhang Y, Jiang L, Li Q. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Hum Vaccin 2010; 6:1028-37; PMID:21150270; http://dx.doi.org/10.4161/hv.6.12.12982
27. Mao Q, Li N, Yu X, Yao X, Li F, Lu F, Zhuang H, Liang Z, Wang J. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol 2012; 157:37-41; PMID:21984267; http://dx.doi.org/10.1007/s00705-011-1136-3
28. Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 2012; 86:11967-76; PMID:22951825; http://dx.doi.org/10.1128/JVI.00902-12
29. Liu CC, Lian WC, Butler M, Wu SC. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 2007; 25:19-24; PMID:16919374; http://dx.doi.org/10.1016/j.vaccine.2006.06.083
30. Quesney S, Marvel J, Marc A, Gerdil C, Meignier B. Characterization of Vero cell growth and death in bioreactor with serum-containing and serum-free media. Cytotechnology 2001; 35:115-25; PMID:19003288; http://dx.doi.org/10.1023/ A:1017589526145
31. Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, Na R, Liang Y, Wang L, Li Q. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 2011; 29:6269-75; PMID:21722686; http://dx.doi.org/10.1016/j.vaccine.2011.06.044